+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded)

Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded)

Cancer 55(2): 323-336

From September 1976 to August 1979 the Pediatric Oncology Group accessed 145 children to study the effectiveness of modified LSA2-L2 therapy for the treatment of non-Hodgkin's lymphoma (NHL). Burkitt's lymphoma patients were ineligible; E-rosette-positive patients with greater than or equal to 25% blasts in the marrow entered after February 1977 were reported separately. Radiotherapy could be used to treat patients with compressive mediastinal disease at diagnosis and was prescribed for those with residual abdominal disease as demonstrated by second-look surgery on completion of induction chemotherapy. Confirmation of diagnosis by the Pathology Panel and Repository Center for Lymphoma Clinical Trials was mandatory. Diagnostic tissues of 131 patients were reviewed. Among 107 evaluable patients, 91 (85%) achieved complete remission. Differences in response rates among the three major histologic groups (lymphoblastic, undifferentiated, and large cell) were of statistical significance, with response being poorest for diffuse undifferentiated lymphoma (P = 0.03). Failure-free survival did not differ significantly for the three major histologic diagnoses. While response rate was lowest for Murphy Stage III patients (79%), the differences among the stages were not significant. Stage was not a significant prognostic factor for failure-free survival (P = 0.08). The number of patients still at risk and the Kaplan-Meier estimate of percentage of patients remaining at risk after 3 years is: Stage I, 8 (100%); Stage II, 10 (67%); Stage III, 28 (57%); Stage IV, 6 (39%); and greater than 25% blasts, 1 (13%). Stage III failure curves for lymphoblastic disease show continuing stepwise failure through 3 years. Among patients with diffuse large cell and undifferentiated disease, most failures occurred by 8 months. M1 and M2 levels of marrow involvement were not prognostic among children with lymphoblastic disease. The presence of a mediastinal mass was a significant factor contributing to failure in children with lymphoblastic disease without marrow involvement. Leucocytosis greater than 10,000/1, was a significant (P = less than 0.001) factor predicting failure-free survival for patients with large cell lymphoma. The delivery of radiotherapy was not a significant factor in achieving remission. No consistent benefit resulted from using radiotherapy to treat postinduction residual disease demonstrated on second-look exploration. The LSA2-L2 regimen was associated with considerable toxicity, severe or worse in 77% and life-threatening to 40% of these patients. Four died of toxicity. However, therapy was given more easily and safely as investigator experience increased.(ABSTRACT TRUNCATED AT 400 WORDS)

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 040930265

Download citation: RISBibTeXText

PMID: 3880656

DOI: 10.1002/1097-0142(19850115)55:2<323::aid-cncr2820550204>3.0.co;2-9

Related references

Primary and secondary chromosome abnormalities are similar in pediatric burkitt lymphoma/burkitt leukemia burkitt-like lymphoma A report of the international pediatric B-cell non-Hodgkin lymphoma Study. Blood 102(11): 373a, November 16, 2003

Results of modified LSA2-L2 protocol with moderate-dose MTX therapy in children with untreated non-Hodgkin's lymphoma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(3): 395-398, 1992

Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. Journal of Clinical Oncology 6(1): 26-33, 1988

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110(1): 179-185, 2007

Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer 64(1): 23-28, 1989

Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. European Journal of Haematology 77(5): 365-371, 2006

non-Hodgkin's lymphoma treated with modified LSA2-L2 protocol--a clinical experience and case report. Gaoxiong Yi Xue Ke Xue Za Zhi 3(6): 419-424, 1987

Non-Hodgkin's lymphoma in children: results of treatment with the modified LSA2-L2 protocol. Medical and Pediatric Oncology 9(5): 483-491, 1981

Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol. Pediatric Hematology and Oncology 3(3): 217-228, 1986

Results of LSA2-L2 therapy in 26 children with non-Hodgkin's lymphoma. Cancer 50(12): 2740-2746, 1982

Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Practical Radiation Oncology 5(2): 85-92, 2015

Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology, Biology, Physics 92(1): 144-152, 2015

Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatric Blood and Cancer 56(1): 70-76, 2010

Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group. Pediatric Blood & Cancer 59(7): 1284-1289, 2012

Results of LSA2-L2 therapy in children with high-risk acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Haematology and Blood Transfusion 28: 62-66, 1983